Adjuvant Chemotherapy in Resected Lung Cancer: Two-Year Experience in a University Hospital
BACKGROUND: Randomized trials have confirmed the benefits of adjuvant chemotherapy in improving survival in resected early-stage non-small-cell lung cancer (NSCLC). The extent to which these results have translated into clinical practice is unknown.
Saved in:
| Main Authors: | Nicole Bouchard, Francis Laberge, Bruno Raby, Sylvie Martin, Yves Lacasse |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2008/462147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC
by: Angelos Vasilopoulos, BS, et al.
Published: (2025-06-01) -
Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
by: L. V. Bolotina, et al.
Published: (2014-07-01) -
Evaluation of the effect of neoadjuvant chemotherapy on the planned resectability of extremity soft-tissue sarcomas
by: Simon Tournemine, et al.
Published: (2025-05-01) -
Predictive Value of Tumor ERCC1 Expression for Treatment Outcomes After Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer
by: Nakata M, et al.
Published: (2025-07-01) -
Adjuvant chemotherapy for gastric cancer
by: I. P. Kolesnyk, et al.
Published: (2015-12-01)